Recently, significant progress has been achieved in understanding the mechanistic consequences of individual pathways affected in HR-ALL, and the resulting selection of therapeutic targets leading to clinical trials using pathway-specific drugs, such as JAK/STAT inhibitors [6]. Here, SOAT1 is linked to acute lymphoblastic leukemia.